Mercodia delivers uncompromising accuracy with specialised ELISA kits
Accuracy that is never compromised, from the laboratory bench to a patient's bedside - this is the guarantee that comes with every product and service from the world-leading immunoassay kit developer, manufacturer and distributor Mercodia.
Accuracy that is never compromised, from the laboratory bench to a patient's bedside - this is the guarantee that comes with every product and service from the world-leading immunoassay kit developer, manufacturer and distributor Mercodia.
Mercodia specialises in enzyme-linked immunosorbent assay (ELISA) for clinical and research applications, particularly within the areas of diabetes, obesity and cardiovascular diseases.
"Running the same samples with an easy-to-use Mercodia ELISA kit in Stockholm, Hong Kong, Madrid or anywhere else will give you the same result - today or in the next 10 years," says CEO Mona Osterberg.
"That is the kind of accuracy, repeatability and usability promise that we have been fulfilling since 1991, when Mercodia's founder, Erling Holmlund, envisioned high-quality ELISA products that cannot fail."
Mercodia exports ELISA kits to more than 100 countries, including China, where diabetes and cardiovascular diseases are fast-growing health concerns. It also provides commissioned services as a one-stop immunoassay partner to research institutions, universities and health care leaders such as Sanofi-Aventis and AstraZeneca.
Showcasing this innovativeness is Mercodia's glucagon ELISA kit, which is expected to break new ground as the most accurate and specific assay of its kind. Launched last month, it is projected to boost sales for Mercodia, which invested extensive resources, years of hard work and in-depth research in the project.
The assay is distinct since it only requires as little as 25 microlitres of sample, and it is highly specific to glucagon, which some researchers believe can revolutionise this field of research.
For developing new applications and improving existing products, Mercodia has partnered with California-based clinical research institute Profil in April, aiming to enhance diabetes and obesity clinical trials.
Present in Asia since 1998, Mercodia is pursuing emerging markets including China, and is keen on finding local partners that share its scientific interests, values and passions.
"We look forward to developing more assays and expanding our services," Osterberg says. "We have a big knowledge base that we are eager to grow and share through high-quality relationships."
http://www.mercodia.com
